VYGR
Voyager Therapeutics, Inc.NASDAQHealthcare$3.96+0.25%ClosedMarket Cap: $236.0M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
1.19
P/S
5.86
EV/EBITDA
-1.66
DCF Value
$-4.62
FCF Yield
-57.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-326.6%
Net Margin
-296.5%
ROE
-51.4%
ROA
-47.5%
ROIC
-56.4%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $15.3M | 100.0% | $-29.9M | $-27.4M | $-0.47 | — |
| FY 2025 | $40.4M | 100.0% | $-131.8M | $-119.7M | $-2.04 | — |
| Q3 2025 | $13.4M | 100.0% | $-30.6M | $-27.9M | $-0.47 | — |
| Q2 2025 | $5.2M | 100.0% | $-36.6M | $-33.4M | $-0.57 | — |
| Q1 2025 | $6.5M | 100.0% | $-34.7M | $-31.0M | $-0.53 | — |
| Q4 2024 | $6.3M | 100.0% | $-38.3M | $-34.5M | $-0.59 | — |
| FY 2024 | $80.0M | 100.0% | $-83.3M | $-65.0M | $-1.13 | — |
| Q3 2024 | $24.6M | 100.0% | $-13.8M | $-9.0M | $-0.16 | — |
| Q2 2024 | $29.6M | -8.0% | $-15.0M | $-10.1M | $-0.18 | — |
| Q1 2024 | $19.5M | 93.9% | $-16.2M | $-11.3M | $-0.20 | — |
| Q4 2023 | $90.1M | 98.5% | $54.1M | $56.4M | $1.25 | — |
| FY 2023 | $250.0M | 63.1% | $122.0M | $132.3M | $2.97 | — |